Published in Front Pharmacol on March 23, 2015
Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration. Pediatr Rheumatol Online J (2016) 0.78
Tumor necrosis factor-α -308 A/G gene polymorphism in children with juvenile idiopathic arthritis: relation to disease activity, damage, and functional status. Clin Rheumatol (2017) 0.75
Juvenile idiopathic arthritis. Lancet (2007) 5.64
Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med (2000) 4.76
Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med (2008) 4.58
Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group. N Engl J Med (1992) 2.62
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52
Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev (2005) 2.42
Methotrexate--how does it really work? Nat Rev Rheumatol (2010) 2.24
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood (2008) 1.89
Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis (2008) 1.78
A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum (2004) 1.71
Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis. Pharmacogenet Genomics (2012) 1.65
Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A (1991) 1.61
Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum (2011) 1.51
5-Aminoimidazole-4-carboxamide ribonucleotide-transformylase and inosine-triphosphate-pyrophosphatase genes variants predict remission rate during methotrexate therapy in patients with juvenile idiopathic arthritis. Rheumatol Int (2014) 1.41
PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics (2011) 1.27
Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child (2003) 1.07
Epigenetic mechanisms of importance for drug treatment. Trends Pharmacol Sci (2014) 1.01
Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis. Ann Rheum Dis (2011) 1.00
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis (2014) 0.97
Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J (2012) 0.97
Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype. Pharmacogenet Genomics (2010) 0.97
Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J (2012) 0.92
Whole blood gene expression profiling predicts therapeutic response at six months in patients with polyarticular juvenile idiopathic arthritis. Arthritis Rheumatol (2014) 0.87
Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases. Pharmacogenomics J (2014) 0.87
Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. Ann Rheum Dis (2013) 0.87
Folate supplementation during methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol (2010) 0.86
Personalized therapies in pediatric inflammatory and autoimmune diseases. Curr Pharm Des (2012) 0.85
Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation. Pharmacogenet Genomics (2014) 0.84
Pharmacogenetics: can genes determine treatment efficacy and safety in JIA? Nat Rev Rheumatol (2014) 0.84
Optimization of pediatric rheumatology therapeutics. Clin Pharmacol Ther (2012) 0.79